Back to Search
Start Over
Preclinical evidence of normal bone with alendronate.
- Source :
-
International journal of clinical practice. Supplement [Int J Clin Pract Suppl] 1999 Apr; Vol. 101, pp. 9-13. - Publication Year :
- 1999
-
Abstract
- This review summarises the results of preclinical studies aimed at elucidating the mode of action of alendronate and assessing its effects on bone quality. Alendronate preferentially localises at bone resorption sites, where the drug inhibits osteoclastic activity. In a variety of estrogen-deficient animal models, alendronate normalised bone turnover, promoted normal mineralisation and increased bone mass and strength. In these studies, bone formed during alendronate therapy was histologically normal and was not associated with spontaneous fractures. Therefore, preclinical studies have established that the antiresorptive activity of alendronate results in the prevention of bone loss and the accretion of normal-quality bone.
- Subjects :
- Alendronate pharmacokinetics
Animals
Autoradiography methods
Bone Density
Bone Resorption drug therapy
Bone Resorption metabolism
Drug Evaluation, Preclinical
Humans
Mice
Microscopy, Electron methods
Osteoclasts drug effects
Osteoporosis prevention & control
Rats
Alendronate pharmacology
Bone and Bones drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1368-504X
- Volume :
- 101
- Database :
- MEDLINE
- Journal :
- International journal of clinical practice. Supplement
- Publication Type :
- Academic Journal
- Accession number :
- 12669735